Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The Lancet Haematology

Venetoclax added to CLIA was safe and active in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, producing high rates of durable MRD-negative remissions and encouraging event-free survival and overall survival.

  • In a study of 50 younger patients with new AML or high risk MDS treated at MDA, CLIA + VEN showed a 95% rate of CR+CRi and a 1 year OS of 85%. 1 patient died during induction and and 2 died of infectious consolidation during consolidation, all of whom were on FLT inhibitors as well.